SUPN Stock Analysis: Supernus Pharmaceuticals | NASDAQ
Drug Manufacturers - Specialty & Generic | NASDAQ, USA | Market Cap: 2.829m USD | 12M Return: 39.4% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 41.8M
EPS Trend: 73.2%
Qual. Beats: 0
Rev. Trend: 88.2%
Qual. Beats: 4
Warnings
Tailwinds
No distinct edge detected
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Supernus Pharmaceuticals is a U.S. biopharmaceutical company headquartered in Rockville, Maryland, that develops and commercializes branded products targeting central nervous system (CNS) disorders. Like most specialty pharma companies in the CNS space, its business model centers on a small number of proprietary, patent-protected drugs sold through wholesalers, specialty pharmacies, and distributors, with revenue concentrated in neurology and psychiatry indications.
The companys commercial portfolio spans ADHD, epilepsy, migraine prophylaxis, Parkinsons disease, and cervical dystonia. Marketed brands include Qelbree (a non-stimulant ADHD treatment), GOCOVRI (Parkinsons dyskinesia), Oxtellar XR and Trokendi XR (extended-release epilepsy/migraine products), APOKYN and XADAGO (advanced Parkinsons), and MYOBLOC (a Type B botulinum toxin for cervical dystonia and chronic sialorrhea). The franchise reflects a common specialty-pharma approach of pairing established molecules with reformulated or extended-release delivery to differentiate against generics.
Supernuss pipeline includes ONAPGO, an FDA-approved therapy for motor fluctuations in advanced Parkinsons, as well as earlier-stage CNS candidates: SPN-817 (a selective acetylcholinesterase inhibitor in Phase 2 for epilepsy and rare pediatric seizure syndromes), SPN-820 (a small molecule in Phase 2 for treatment-resistant depression, partnered with Navitor Inc.), and SPN-443 (a Phase 1 stimulant for ADHD). Development activity is concentrated in CNS, a therapeutic area where clinical trial timelines and regulatory pathways are typically long and capital-intensive.
The company distributes its products through pharmaceutical wholesalers, specialty pharmacies, and distributors, a typical go-to-market structure for U.S. specialty pharma. Supernus was incorporated in 2005 and listed on Nasdaq in 2012 under the ticker SUPN, operating within the Health Care sectors Pharmaceuticals sub-industry.
- Qelbree prescription growth drives ADHD segment revenue higher
- ONAPGO commercial launch expands Parkinsons franchise after FDA approval
- Trokendi XR generic erosion pressures legacy epilepsy sales
| Net Income: -29.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.05 > 0.02 and ΔFCF/TA -6.64 > 1.0 |
| NWC/Revenue: 46.04% < 20% (prev 60.75%; Δ -14.71% < -1%) |
| CFO/TA 0.06 > 3% & CFO 83.3m > Net Income -29.0m |
| Net Debt (-343.3m) to EBITDA (51.7m): -6.64 < 3 |
| Current Ratio: 1.96 > 1.5 & < 3 |
| Outstanding Shares: last quarter (57.6m) vs 12m ago 3.19% < -2% |
| Gross Margin: 89.42% > 18% (prev 88.42%; Δ 1.00% > 0.5%) |
| Asset Turnover: 54.55% > 50% (prev 49.58%; Δ 4.97% > 0%) |
| Interest Coverage Ratio: -12.77 > 6 (EBIT TTM -45.6m / Interest Expense TTM 3.57m) |
| A: 0.24 (Total Current Assets 731.6m - Total Current Liabilities 373.9m) / Total Assets 1.50b |
| B: 0.34 (Retained Earnings 515.6m / Total Assets 1.50b) |
| C: -0.03 (EBIT TTM -45.6m / Avg Total Assets 1.42b) |
| D: 2.54 (Book Value of Equity 1.08b / Total Liabilities 423.9m) |
| Altman-Z'' = 5.14 = AAA |
| DSRI: 1.08 (Receivables 182.2m/145.6m, Revenue 776.8m/668.0m) |
| GMI: 0.99 (GM 88.42% / 89.42%) |
| AQI: 1.01 (AQ_t 0.49 / AQ_t-1 0.48) |
| SGI: 1.16 (Revenue 776.8m / 668.0m) |
| TATA: -0.07 (NI -29.0m - CFO 83.3m) / TA 1.50b) |
| Beneish M = -2.86 (Cap -4..+1) = A |
As of July 14, 2026, the stock is trading at USD 47.35 with a total of 667,488 shares traded. Over the past week, the price has changed by +0.23%, over one month by +7.96%, over three months by -5.21% and over the past year by +39.43%.
Current recommended Stop Loss: 45.20 (which is 4.5% or 1.3 ATR below the current price).
Supernus Pharmaceuticals has received a consensus analysts rating of 3.80. Therefore, it is recommended to hold SUPN.
- StrongBuy: 2
- Buy: 0
- Hold: 3
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 63.5 | 34.1% |
P/E Forward = 20.1613
P/S = 3.6423
P/B = 2.7198
P/EG = 1.47
Revenue TTM = 776.8m USD
EBIT TTM = -45.6m USD
EBITDA TTM = 51.7m USD
Long Term Debt = 30.3m USD (estimated: total debt 40.9m - short term 10.6m)
Short Term Debt = 10.6m USD (from shortTermDebt, last quarter)
Debt = 40.9m USD (from shortLongTermDebtTotal, last quarter) (leases 40.9m already included)
Net Debt = -343.3m USD (calculated: Debt 40.9m - CCE 384.2m)
Enterprise Value = 2.49b USD (2.83b + Debt 40.9m - CCE 384.2m)
Interest Coverage Ratio = -12.77 (Ebit TTM -45.6m / Interest Expense TTM 3.57m)
EV/FCF = 30.23x (Enterprise Value 2.49b / FCF TTM 82.2m)
FCF Yield = 3.31% (FCF TTM 82.2m / Enterprise Value 2.49b)
FCF Margin = 10.59% (FCF TTM 82.2m / Revenue TTM 776.8m)
Net Margin = -3.74% (Net Income TTM -29.0m / Revenue TTM 776.8m)
Gross Margin = 89.42% ((Revenue TTM 776.8m - Cost of Revenue TTM 82.2m) / Revenue TTM)
Gross Margin QoQ = 88.74% (prev 89.13%)
Tobins Q-Ratio = 1.66 (Enterprise Value 2.49b / Total Assets 1.50b)
Interest Expense / Debt = 8.73% (Interest Expense 3.57m / Debt 40.9m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -36.0m (EBIT -45.6m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 1.96 (Total Current Assets 731.6m / Total Current Liabilities 373.9m)
Debt / Equity = 0.04 (Debt 40.9m / totalStockholderEquity, last quarter 1.08b)
Debt / EBITDA = -6.64 (Net Debt -343.3m / EBITDA 51.7m)
Debt / FCF = -4.17 (Net Debt -343.3m / FCF TTM 82.2m)
Total Stockholder Equity = 1.06b (last 4 quarters mean from totalStockholderEquity)
RoA = -2.04% (Net Income -29.0m / Total Assets 1.50b)
RoE = -2.73% (Net Income TTM -29.0m / Total Stockholder Equity 1.06b)
RoCE = -4.17% (EBIT -45.6m / Capital Employed (Equity 1.06b + L.T.Debt 30.3m))
RoIC = -3.28% (negative operating profit) (NOPAT -36.0m / Invested Capital 1.10b)
WACC = 7.04% (E(2.83b)/V(2.87b) * Re(7.04%) + D(40.9m)/V(2.87b) * Rd(8.73%) * (1-Tc(0.21)))
Discount Rate = 7.04% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 93.86 | Cagr: 2.06%
[DCF] Terminal Value 73.10% ; FCFF base≈114.7m ; Y1≈100.6m ; Y5≈81.3m
[DCF] Fair Price = 28.39 (EV 1.30b - Net Debt -343.3m = Equity 1.65b / Shares 58.0m; r=8.35% [WACC [floored]]; 5y FCF grow -15.0% → 2.50% )
EPS Correlation: 73.18 | EPS CAGR: 14.98% | SUE: -0.22 | # QB: 0
Revenue Correlation: 88.21 | Revenue CAGR: 7.60% | SUE: 1.93 | # QB: 4
EPS current Quarter (2026-06-30): EPS=0.46 | Chg30d=+0.00% | Revisions=+25% | Analysts=2
EPS next Quarter (2026-09-30): EPS=0.67 | Chg30d=+0.00% | Revisions=+0% | Analysts=3
EPS current Year (2026-12-31): EPS=2.49 | Chg30d=+0.00% | Revisions=+0% | GrowthEPS=+3.8% | GrowthRev=+20.6%
EPS next Year (2027-12-31): EPS=4.34 | Chg30d=+0.00% | Revisions=+0% | GrowthEPS=+74.7% | GrowthRev=+18.0%
[Analyst] Revisions Ratio: +25% (up=1, down=0)